Journal of Clinical Oncology
Articles in this Issue
First-line lenvatinib versus dabrafenib plus trametinib (D+T) in <i>BRAF</i> -mutated differentiated thyroid cancer (DTC): Insights from real-world data.
6052 Background: BRAF mutations are present in approximately 40%–60% of patients with DTC. Lenvatinib...
Pre-operative lymph node staging in localized esophageal cancer using a high-sensitivity ctDNA assay.
e16111 Background: Accurate lymph node (LN) staging remains essential in esophageal cancer (EC) treated with neoadjuvant c...
Neoadjuvant tislelizumab plus oxaliplatin and S-1 for locally advanced Siewert type II esophagogastric junction adenocarcinoma: A prospective multicenter phase II study.
4091 Background: Adenocarcinoma of the esophagogastric junction (AEG) is a malignant tumor with high morbidity and mortali...
Trends in clinical characteristics, outcomes, and prognostic factors in melanoma: A retrospective real-world analysis.
e21586 Background: Melanoma remains a challenging heterogeneous malignancy with outcomes influenced by its stage at presen...
Next-generation cancer organoids 2.0 in precision cancer medicine: Patient-derived pancreatic ductal adenocarcinoma organoids model to describe drug sensitivity and complexity of tumor biology.
4221 Background: Organotypic models of patient-specific tumors are revolutionizing our understanding of cancer heterogenei...
Genomic signature–based risk score for PARP inhibitor response in <i>BRCA</i> -mutated ovarian cancer: A whole-exome sequencing analysis.
5547 Background: To identify whole-exome sequencing (WES)–based genomic signatures associated with response to poly(ADP-ri...
Precemtabart tocentecan (Precem-TcT, M9140), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic pancreatic ductal carcinoma (mPDAC): Results from the phase 1b/2 PROCEADE-PanTumor PDAC substudy.
4199 Background: CEACAM5 is overexpressed in many cancers, including PDAC, with limited expression in normal tissues. Prec...
Deep learning–derived MRI features for risk stratification in post-surgical <i>IDH</i> -mutant glioma.
e14006 Background: IDH-mutant gliomas undergo long periods of observation after radiochemotherapy before undergoing malign...
Adenoid basal carcinoma: An NCDB study of demographic and socioeconomic factors.
e21550 Background: Adenoid basal carcinoma (ABC) is a rare, indolent variant of basal cell carcinoma that often presents a...
A randomized phase II dose optimization study for alveltamig (ZG006), a trispecific T-cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma (ZG006-003).
4004 Background: Alveltamig (ZG006) is an innovative trispecific T cell engager (Tri-TCE) targeting two distinct DLL3 epit...
Surgical management of locally advanced pancreatic cancer with arterial resections and reconstructions in elderly patients: Short- and long-term comparative outcomes.
e16425 Background: Pancreatic cancer predominantly affects older adults, with peak incidence in the seventh and eighth dec...
Ripretinib as preoperative therapy in patients with potentially resectable advanced gastrointestinal stromal tumors after imatinib failure: Final analysis of a prospective, multicenter study.
11537 Background: Cytoreductive surgery may improve outcomes in patients with locally advanced or metastatic gastrointesti...
The SURVIVE study: Re-evaluating follow-up in early breast cancer.
TPS658 Background: For decades, international guidelines unanimously recommended limiting routine follow-up in early breas...
Characterizing the prevalence of antibody-drug conjugated–induced nausea and vomiting (ADCINV) in patients with cancer.
e24052 Background: Antibody-drug conjugates (ADC) have emerged as an important part of systemic treatment across disease s...
[ <sup>18</sup> F] F-NYM124 for safety, imaging, and dosimetry in patients with indeterminate renal masses.
e16513 Background: With limitations of conventional imaging and biopsy, accurate, non-invasive techniques to detect in pat...
Cumulative toxicity assessed by area-under-the-curve (AUC) in targeted therapy versus chemotherapy for advanced <i>EGFR</i> -mutant NSCLC.
12141 Background: Current adverse event (AE) reporting standards emphasize peak toxicity, which may inadequately capture t...
Implementation of a telephone genetic screening program in breast cancer survivorship in the Bronx: A health care delivery quality improvement project.
e22632 Background: Hereditary screening and testing can identify individuals with a personal or family history harboring g...
Real-world outcomes of lifileucel in advanced melanoma: A single-institution experience.
9552 Background: Lifileucel (Amtagvi), an autologous tumor-infiltrating lymphocyte (TIL) therapy, was FDA approval for unr...
Developing an integrated survivorship checklist for LMIC: Feasibility and results from a tertiary care center.
e24135 Background: Survivorship clinics are vital for identifying health and quality-of-life issues among cancer survivors...
Comparative analysis of adjuvant chemoradiotherapy vs. tegafur/gimeracil/oteracil monotherapy vs. observation alone in gastric cancer patients after gastrectomy plus D2 lymph node dissection: A single-center 15-year retrospective study.
e16096 Background: The surgical management of gastric cancer in lymph nodes dissection (LND) differ between Eastern and We...
A randomized, non-comparative, multicenter phase II trial of neoadjuvant becotatug vedotin alone or combined with immune checkpoint inhibitors (penpulimab/ivonescimab) in resectable locally advanced head and neck squamous cell carcinoma.
TPS6135 Background: The efficacy and safety of neoadjuvant therapy for resectable locally advanced head and neck squamous...
From plenary to practice: A large language model (LLM)–based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoption.
1583 Background: Landmark trials define standard-of-care (SOC), yet the translation of trial evidence into routine practic...
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer: TRAP-OLIGO study (WJOG11118L).
8571 Background: Several clinical trials have demonstrated that local ablative therapy (LAT) to all lesions, including pri...
Global trends in leukemia-related disability-adjusted life years and mortality across socio-demographic index regions, 1980–2023.
e18516 Background: Leukemia remains a substantial contributor to global morbidity and mortality, with marked variation in...
Impact of physical exercise on psychological status and evaluation of exercise discussions during oncology consultations in Syria.
e13621 Background: Physical activity (PA) is a key component of supportive cancer care and is associated with improved psy...